Graft-versus-host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-05-19FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) filed by Astellas Pharma US, Inc.